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FOSL1 is a novel
mediator of endotoxin/
lipopolysaccharide‑induced
pulmonary angiogenic signaling
Christopher R. Nitkin1,4*, Sheng Xia1,4, Heather Menden1, Wei Yu1, Min Xiong2,3,
Daniel P. Heruth2, Shui Qing Ye1,5 & Venkatesh Sampath1
Systemic sepsis is a known risk factor for bronchopulmonary dysplasia (BPD) in premature infants, a
disease characterized by dysregulated angiogenesis and impaired vascular and alveolar development.
We have previoulsy reported that systemic endotoxin dysregulates pulmonary angiogenesis
resulting in alveolar simplification mimicking BPD in neonatal mice, but the underlying mechanisms
remain unclear. We undertook an unbiased discovery approach to identify novel signaling pathways
programming sepsis-induced deviant lung angiogenesis. Pulmonary endothelial cells (EC) were
isolated for RNA-Seq from newborn C57BL/6 mice treated with intraperitoneal lipopolysaccharide
(LPS) to mimic systemic sepsis. LPS significantly differentially-regulated 269 genes after 6 h,
and 1,934 genes after 24 h. Using bioinformatics, we linked 6 h genes previously unknown to be
modulated by LPS to 24 h genes known to regulate angiogenesis/vasculogenesis to identify pathways
programming deviant angiogenesis. An immortalized primary human lung EC (HPMEC-im) line
was generated by SV40 transduction to facilitate mechanistic studies. RT-PCR and transcription
factor binding analysis identified FOSL1 (FOS like 1) as a transcriptional regulator of LPS-induced
downstream angiogenic or vasculogenic genes. Over-expression and silencing studies of FOSL1
in immortalized and primary HPMEC demonstrated that baseline and LPS-induced expression of
ADAM8, CXCR2, HPX, LRG1, PROK2, and RNF213 was regulated by FOSL1. FOSL1 silencing impaired
LPS-induced in vitro HPMEC angiogenesis. In conclusion, we identified FOSL1 as a novel regulator of
sepsis-induced deviant angiogenic signaling in mouse lung EC and human fetal HPMEC.
Bronchopulmonary dysplasia (BPD) is a developmental lung disorder characterized by simplified alveoli and
dysmorphic pulmonary v asculature1–6. BPD affects approximately 40% of infants born at ≤ 28 weeks gestational
age with up to 29% m
 ortality7. Recent studies have found that maternal chorioamnionitis increases the incidence of BPD and perinatal m
 ortality8, and postnatal sepsis or pneumonia increases the risk of preterm infants
9
developing BPD . While oxygen toxicity, mechanical ventilation, and inflammation are traditional risk factors
for the development of BPD, systemic sepsis has emerged as a significant risk factor for BPD10–13. Systemic sepsis
caused by Gram-positive and Gram-negative bacteria is common in premature infants, and is associated with
BPD9,14–16. in addition to airway colonization with Gram negative bacilli correlates with severe B
 PD17. However,
the mechanisms underlying sepsis-induced neonatal acute lung injury and alveolar remodeling seen in BPD
remain understudied3,18–21. We have previously shown that postnatal systemic lipopolysaccharide (LPS) disrupts
lung development in newborn mice, leading to alveolar simplification in a Nox2-dependent m
 anner1. However,
relatively little is known about the impact of LPS on the developing lung vasculature.
In human BPD and hyperoxia models of experimental BPD, several researchers have reported that angiogenesis is impaired and vessel density is decreased6,22,23. However, other studies have implicated that dysangiogenesis with increased microvascular growth but dysmorphic arborization is seen in human disease24,25. Our
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prior work suggests that systemic LPS in mice programs a dysangiogenesis phenotype, which also results in
alveolar remodeling26.
Inflammation alters vascular development, as infants with BPD who experienced sepsis have increased risk of
pulmonary hypertension27 and biomarkers of angiogenesis such as VEGFA, KDR, endostatin, and angiopoietin-2
are altered in infants who develop subsequently B
 PD28. Despite the accumulating evidence for sepsis-induced
aberrant angiogenesis to program vascular remodeling in the developing lung, the mechanisms by which LPS
disrupts angiogenesis or programs dysangiogensis vascular phenotypes in the developing lung reamain unclear.
Therefore, the objective of this study was to identify novel pathways by which systemic sepsis programs aberrant angiogenesis in the developing lung using an unbiased approach involving RNA-Seq and bioinformatics
methods. By combining discovery-based RNA sequencing studies in a neonatal mouse model of sterile sepsis
complemented by validation strategies using genetic manipulation in primary fetal human lung endothelial cell
(EC) and an immortalized lung EC line we developed, we identify the transcription factor FOSL1 (FOS like 1,
also known as FRA-1, FOS-related antigen 1), as a novel regulator of endotoxin-mediated dysangiogenesis in
the developing lung.

Results

Lung endothelium transcriptome profiling identifies inflammatory, immune, and several
pathways differentially regulated by systemic endotoxin in the developing lung at 6 h. To

identify novel targets induced by systemic endotoxin, mouse lung EC were isolated from 4-day old (DOL-4)
LPS-treated (2 mg/kg intraperitoneal, i.p) and control littermates (n = 3/group) after 6 h, and RNA-Seq was
performed. Ingenuity Pathway Analysis (IPA) was used to analyze 24,392 genes, of which 269 were significantly
up- or down-regulated with p and q < 0.05 (Fig. 1A). IPA-predicted physiological system development and functional categories induced by LPS were mainly involved in leukocyte recruitment and function, as expected for a
pro-inflammatory stimulus (Table S1). Angiogenesis as a component of “Cardiovascular System Development
and Function” was confirmed as predicted increased with LPS treatment, significant across the data set at 6 h
(p = 2.84 × 10–18) with + 3.422 z-score of activation (Fig. 1B).
After preliminary identification of significant changes of gene expression, the IPA Knowledge Base (KB) of
~ 5.9 million citations was used to efficiently filter RNA-Seq gene expression data. We targeted those genes that
were previously not known to be altered with LPS treatment and showed significant changes. This yielded 97
genes that were significantly up- and down-regulated with p and q < 0.05 (Table S2). We validated 6/97 targets,
identified by RNA-Seq with RT-PCR (Real-Time PCR); Fosl1, Adam8, Cxcr2, Plac8, Fcgr3, and Hpx in primary
murine pulmonary EC isolated under similar experimental conditions as RNA-seq data in independent mouse
samples (n = 6/group) (Fig. 1C). Genes were chosen for validation based on below described IPA analysis linking
6 h and 24 h sequencing data.

Lung endothelium transcriptome profiling identifies angiogenic or vasculogenic genes differ‑
entially regulated in the neonatal lung with systemic endotoxin at 24 h. To identify novel LPS-

induced angiogenesis and vasculogenesis pathways, RNA-Seq was performed as above on mouse lung EC isolated from LPS-treated and control DOL-4 mice 24 h after LPS exposure. IPA identified 1,934 genes which were
significantly up- or down-regulated with p and q < 0.05 (Fig. 2A). IPA-predicted physiological system development and function categories induced by LPS were mainly involved in leukocyte recruitment and function
(Table S3). Angiogenesis as a component of “Cardiovascular System Development and Function” was confirmed
as predicted increased with LPS treatment, significant across the data set at 24 h (p = 2.68 × 10–26) with + 2.474
z-score of activation (Fig. 2B). As before, IPA was used to efficiently filter RNA-Seq gene expression data, identifying genes known to be important in angiogenesis or vasculogenesis. This yielded 235 genes (see Table S4).
Using Pubmed searches, we identified Adam8, Cxcr2, Rnf213, and Hpx as genes previously implicated in regulating angiogenesis or vasculogenesis in developmental or pathological conditions, but not reportedly downstream
of LPS or its receptor Toll Like receptor 4. We validated expression of these genes in independent mouse lung EC
samples obtained 24 h after i.p. LPS injection (Fig. 2C).

Discovery of novel transcriptional links between LPS and angiogenesis/vasculogenesis. As
we were investigating novel links between genes induced by LPS at 6 h that can transcriptionally upregulate
angiogenic/vasculogenic genes at 24 h, we used IPA to make connections between genes at 6 h not known to be
induced by LPS, and genes at 24 h known to be involved in angiogenesis or vasculogenesis (Fig. 3A). Only genes
found to have ≥ 50% increase in expression were pursued. Connections between 6 and 24 h genes were based
solely on transcriptional regulation in the IPA. Non-transcriptional interactions such as protein–protein interactions or phosphorylation, etc. were initially explored but not pursued, and are described in the Supplementary
material (Table S5). Additionally, to maximize impact, only 6 h genes with ≥ 3 downstream targets at 24 h were
investigated, while genes with < 3 downstream targets are shown in the Supplementary material (Table S5).
Six genes (F10, Fcgr2a, Fosl1, Ndrg1, Selplg, Zbtb16) were induced 6 h after LPS in mouse lung EC, and found
to have ≥ 3 transcriptional relationships with 24 h downstream angiogenic/vasculogenic targets. Three of these
targets (F10, Ndrg1, Selplg) were eliminated based on literature review, as these were not novel LPS/TLR targets
. This left us with Fcgr2a, Fosl1, and Zbtb16 as potential target genes induced early with LPS that transcriptionally regulated 24 h angiogenic genes (Fig. 4). Fcgr2a is not a transcription factor, Zbtb16 was not validated by
RT-PCR, so these were excluded. This left Fosl1 as the sole remaining target.
Creation of immortalized human pulmonary lung endothelial cell line (HPMEC‑im). We pro-

ceeded to establish functional relationships between FOSL1 and downstream targets in an in vitro model. We
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Figure 1.  RNA-seq data from lung endothelial cells isolated from DOL-4 mice treated with LPS for 6 h. (A)
Heatmap of differentially expressed genes (n = 3); (B) top pathways identified in Ingenuity Pathway Analysis
as activated; and (C) validation RT-PCR in primary mouse lung endothelial cells (n = 6). Data presented at
mean ± standard deviation, *p < 0.001 between LPS-treated and saline control baseline by one-sample, two-tailed
Student’s t test as all data were normally distributed. Graphs created in SPSS 26 for Mac (https://www.ibm.com/
analytics/spss-statistics-software) and image assembled in Adobe Illustrator 24.1.0 for Mac (https://www.adobe
.com/products/illustrator.html).

used 19-week gestation, male primary HPMEC (ScienCell), derived from neonatal lungs. However, these cells
do not allow plasmid-mediated genetic manipulation studies as they are fragile. We therefore used primary
HPMEC to generate HPMEC-im using SV40 large antigen transformation. Ets-related gene (ERG) and VCAM1 expression, and oxidized lipoprotein uptake confirmed preservation of EC phenotype (Fig. 5A). To extend
RNA-Seq and IPA findings into human cells and to serve as a baseline for mechanistic studies, RT-PCR assessment of both the 6 h genes not previously known to be regulated by LPS and the 24 h known angiogenesis and
vasculogenesis genes was undertaken.

RT‑PCR assessment of novel genes activated by LPS linked to angiogenesis and vasculogen‑
esis genes in HPMEC‑im. Five genes identified from our 6 h RNA sequencing data were assessed with RT-

PCR in HPMECs, including FOSL1, ADAM8, and FCGR3, as well as CXCR2 and CXCL10 which were included
for validating LPS-induced cytokine expression (Fig. 5B). FOSL1 had multiple multiple connections to differentially-expressed 24 h angiogenesis genes, and it was the only transcription factor identified. Therefore, FOSL1
(FOS like 1, Fra-1, AP-1 transcription factor subunit) was further explored as an early EC gene upregulated
with LPS that could potentially induce expression of downstream genes involved in angiogenesis and vasculoScientific Reports |
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Figure 2.  RNA-seq data from lung endothelial cells isolated from DOL-4 mice treated with LPS for 24 h. (A)
Heatmap of differentially expressed genes (n = 3); (B) top pathways identified in Ingenuity Pathway Analysis
as activated; and (C) validation RT-PCR in primary mouse lung endothelial cells (n = 6). Data presented at
mean ± standard deviation, *p < 0.001 between LPS-treated and saline control baseline by one-sample, two-tailed
Student’s t test as all data were normally distributed). Graphs created in SPSS 26 for Mac (https://www.ibm.com/
analytics/spss-statistics-software) and image assembled in Adobe Illustrator 24.1.0 for Mac (https://www.adobe
.com/products/illustrator.html).
genesis. IPA-KB analysis of FOSL1 and the 235 angiogenesis/vasculogenesis genes at 24 h above revealed ten of
the 24 h genes had a transcriptional relationship with FOSL1: Ccl2, Ccnd1, Cd44, Il-1β, Mmp13, Mmp9, Plau,
Plaur, Snai2, and TNF. However, many of these have been reported to be linked with LPS in the literature (e.g.,
Mmp-9), did not seem relevant to angiogenesis (e.g., Cd44), or were not specific for angiogenesis (e.g., Tnf, Il-1β).
Therefore, the list of 24 h angiogenic/ vasculogenic genes was expanded beyond those only predicted by IPA to
be linked to 6 h genes.
We then focused our search to genes (a) not reported to be downstream of LPS, (b) with at least a twofold increase in expression, and (c) not known to be linked to FOSL1 in the IPA-KB. This resulted in a list of
15 potential genes of interest: Adam8, Aif1, Fermt3, Hif-3α, Il-18bp, Lrg1, Myl7, Prkcb, Prok2, Rnf213, S1pr5,
Sema4d, Spink5, Syk, and Sp100a. As these novel relationships were outside of the validated IPA-KB, JASPAR
analysis was performed to identify transcriptional relationships from FOSL1, and indicated eight of these genes
may have FOSL1-binding sites in the human promoter (Fig. 3B), including ADAM8, HIF-3α, LRG1, PRKCB,
PROK2, SPINK5, AND SP100A (Fig. 4). RNF213 and HPX were also included based on previous preliminary
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Of these, four angiogenesis/vasculogenesis genes
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Figure 3.  Bioinformatics analysis of data. (A) IPA-generated map linking FOSL1 to angiogenesis or
vasculogenesis genes; (B) Identification of targets downstream of FOSL1 by JASPAR ranked by score. Image
created in Ingenuity Pathway Analysis (https://digitalinsights.qiagen.com/products-overview/discovery-insig
hts-portfolio/analysis-and-visualization/qiagen-ipa/) and assembled in Adobe Illustrator 24.1.0 for Mac (https://
www.adobe.com/products/illustrator.html).

(ADAM8, MDK, RNF213, SP100) were confirmed to be upregulated with LPS in primary HPMEC (18 weeks
gestation, female) and HPMEC-im (19-week gestation, male) (Fig. 5C) by RT-PCR.

Overexpression of FOSL1 increases expression of angiogenesis and vasculogenesis genes. To
validate our JASPAR analysis and investigate whether FOSL1 actually regulates the in silico-identified downstream targets, we used an overexpression strategy. An expression plasmid containing FOSL1 cDNA was cloned
and transfected in HPMEC-im with and without LPS treatment. We obtained > 150 -fold increased expression
of FOSL1 with transfection in HPMEC-im [C + vector vs. C + Fosl1; 1.05 ± 0.2 vs. 159 ± 55.3, < 0.001, n = 5]. Similarly, we noted ≈ 200 fold increase in FOSL1 expression in LPS-treated HPMEC-Im [LPS + vector vs. LPs + Fosl1;
2.065 ± 0.56 vs. 199 ± 70.4, < 0.001, n = 5]. RT-PCR of angiogenesis or vasculogenesis genes revealed that FOSL1
overexpression alone stimulated increased gene expression of ADAM8, CXCR2, HPX, LRG1, PROK2, and
RNF213 (Fig. 6A) by 24–56% above non-transfected controls, though not significantly. Compared to FOSL1
overexpression or LPS treatment independently, combined FOSL1 overexpression and LPS treatment resulted in
significant induction of ADAM8, CXCR2, HPX, LRG1, PROK2, and RNF213 in HPMEC-im (Fig. 6A). Finally,
combined FOSL1 overexpression and LPS treatment resulted in significant increases in gene expression compared to controls without FOSL1 transfection or LPS treatment. HIF-3α expression did not change with FOSL1
overexpression, and served as negative control. IL-1α expression, which is known to be negatively regulated
by FOSL129, served as an additional control to validate FOSL1-dependent LPS-mediated gene expression in
HPMEC. These data demonstrate that FOSL1 transcriptionally regulates native, and synergistically, LPS-sensitive gene expression of identified targets.
To investigate whether FOSL1 directly binds to the promoter region of identified targets after LPS treatment
we performed chromatin immunoprecipitation (ChIP). We noted that FOSL1 robustly bound to the promoters of
ADAM8, HPX, LRG1, PROK2, and RNF213 at baseline, indicating baseline regulation of these targets by FOSL1
(Fig. 6B). FOSL1 binding to the promoter regions of ADAM8, PROK2, and RNF213 increased by 86.7 to 100.4%,
respectively, 7 h after LPS treatment in HPMEC-im, suggesting LPS-induced transcriptional activation of genes
in HPMEC-im (Fig. 6C). Increased expression of downstream angiogenic genes with FOSL1 overexpression, and
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Figure 4.  Flowchart of gene identification. Describing identification of genes of interest, starting from
identification of genes with statistically significant changes in expression at 6 h that were not known to be
influenced by LPS, removal of non-novel findings, RT-PCR validation and linkage to genes with statistically
significant changes in expression at 24 h that were known to be angiogenic or vasculogenic, had at least two-fold
change in expression, and not found to be linked to Fosl1 or LPS in the IPA-KB, validated by RT-PCR resulted in
the final list of Prok2, Lrg1, Adam8, and Rnf213. Image created in Adobe Illustrator 24.1.0 for Mac (https://www.
adobe.com/products/illustrator.html).
binding of FOSL1 to the promoter regions of target genes support the role of FOSL1 in mediating LPS-induced
lung EC angiogenenic signaling.

FOSL1 silencing decreases LPS‑induced expression of angiogenesis and vasculogenesis
genes. We next explored a loss of function approach to complement our overexpression studies. Here, pri-

mary HPMECs (not transformed) were transfected with FOSL1-siRNA with and without LPS treatment. After
confirming knockdown [C vs. si-FOSL1; 1.0 ± 0.1 vs. 0.49 ± 0.06, p < 0.03, n = 4] of FOSL1 expression (Fig. 7A),
RT-PCR of angiogenesis or vasculogenesis genes was carried out. Silencing FOSL1 alone significantly reduced
expression of ADAM8, HPX, LRG1, CXCR2, and PROK2 by 26–41% compared to scrambled siRNA controls.
FOSL1 silencing suppressed LPS-induced expression of ADAM8, HPX, LRG1, CXCR2, and PROK2 (Fig. 7B) by
29–73%. IL8, TNFα, and ICAM-1 were included for validation as positive controls. These data confirm the LPSinduced expression of angiogenic and vasculogenic genes is suppressed by silencing FOSL1 in primary lung EC.
Taken in conjunction with prior overexpression data in HPMEC-im, these data imply that induction of target
genes after LPS treatment is FOSL1-dependent.
We next examined the impact of FOSL1 in regulating angiogenic sprouting in primary HPMEC by pursuing a matrigel-based angiogenesis assay in HPMEC. LPS induced robust in vitro angiogenesis in matrigel as
evidenced by increased branches and networks (confluence of ≥ 2 branches). LPS-induced angiogenesis was
strongly suppressed by FOSL1 silencing (Fig. 7C–E). These data demonstrate that FOSL1 regulates LPS-induced
in vitro angiogenesis.
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Figure 5.  Validation of cell line as endothelial cells. (A) expression of ERG, CDH5, and vWF by
immunoflourescence, and uptake of AcLDL; (B) assessment of novel LPS genes after treatment of primary
HPMECs (n = 3) and HPMEC line (n = 4) with LPS for 6 h (p values determined by one-sample, two-tailed
Student’s t test); and (C) assessment of angiogenesis or vasculogenesis genes after treatment of primary
HPMECs (n = 3) and HPMEC line (n = 5) with LPS for 24 h (p values determined by one-sample, two-tailed
Student’s t test; all data were normally distributed except 24 h primary HPMEC LRG1 which was assessed with
one-sample Wilcoxon signed rank test). Data presented at mean ± standard deviation. *p < 0.05, **p < 0.01,
***p < 0.001 between LPS-treated and saline control baseline. Graphs created in SPSS 26 for Mac (https://www.
ibm.com/analytics/spss-statistics-software) and image assembled in Adobe Illustrator 24.1.0 for Mac (https://
www.adobe.com/products/illustrator.html).

Discussion

Although sepsis is known to promote the vascular and alveolar remodeling underlying bronchopulmonary
dysplasia, the mechanisms by which inflammation can modulate pulmonary angiogenesis have not been fully
defined. In this unbiased, hypothesis-generating study, we performed transcriptome profiling on lung EC in a
rodent model of systemic sepsis, and identified FOSL1 as a novel early target gene not previously described to
be transcriptionally regulated by LPS. This novel transcriptional regulator was then linked to the angiogenesis
or vasculogenesis genes LRG1, RNF213, and Sp100, which have previously not been reported to be downstream
of LPS or TLR signaling. Complementary overexpression and silencing approaches in a HPMEC-im line we
generated as well as primary fetal HPMEC validated the LPS-FOSL1-angiogenesis/vasculogenesis pathway by
revealing dependence of basal angiogenesis and vasculogenesis gene expression on FOSL1. Finally, impaired
in vitro angiogenesis in FOSL1-deficient ECs strongly implicates the transcription factor FOSL1 as a central
mediator of inflammation-induced pulmonary EC angiogenesis.
Previous studies in premature infants and experimental models of BPD suggest that dysregulation of angiogenesis is important for BPD pathogenesis3,18. For example, in rodent models of BPD, hyperoxia leads to
decreased angiogenesis through ERK1/2-dependent s ignaling19. Similarly, hyperoxia variably induces expression
of angiogenic genes such as the angiopoietins, platelet derived growth factors, and vascular endothelial growth
factor in rats20, culminating in a BPD-like phenotype. Angiopoietin-1 has been shown to ameliorate experimental
BPD in a rodent model21, while angiopoietin-2 worsens hyperoxia-mediated lung injury in nitric oxide- synthase
2-deficient mice30, and increased angiopoietin-2 is associated with BPD in preterm infants31. Our group has
previously shown that LPS treatment of newborn rodents recapitulates the alveolar simplification and impaired
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Figure 6.  FOSL1 overexpression results. Overexpression of FOSL1 in HPMEC-im experiments, including (A)
effect of LPS treatment, FOSL1 overexpression, and combined LPS treatment plus FOSL1 overexpression on
angiogenesis or vasculogenesis gene expression (n = 5 per condition) (*p < 0.05 between LPS-treated and saline
control; §p < 0.05, §§p < 0.01 between vector:LPS and FOSL1:LPS; by one-way ANOVA and post-hoc Tukey
tests [HPX, RNF213, IL-1α] or Krukal-Wallis and post-hoc Mann–Whitney tests [ADAM8, CXCR2, LRG1,
PROK2]); (B) ChIP experiments demonstrating pull-down of downstream target genes by FOSL1 (n = 5 per
condition, presented as mean ± standard deviation with *p < 0.05, **p < 0.01, ***p < 0.001 by one-sample, twotailed Student’s t test [LRG1, PROK2, RNF213] or one-sample Wilcoxon signed rank test [ADAM8]; and (C)
ChIP experiments demonstrating increased binding of FOSL1 to target gene promoters after LPS stimulation
(n = 5 per condition, presented as mean ± standard deviation with *p < 0.05, **p < 0.01, ***p < 0.001 by onesample Wilcoxon signed rank test). Graphs created in SPSS 26 for Mac (https://www.ibm.com/analytics/spssstatistics-software) and image assembled in Adobe Illustrator 24.1.0 for Mac (https://www.adobe.com/products/
illustrator.html).
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Figure 7.  FOSL1 silencing results. siRNA silencing of FOSL1 experiments, including (A) demonstration of
FOSL1 knock-down (n = 4, by one-way ANOVA and post-hoc Tukey tests); (B) effect of LPS treatment, FOSL1
overexpression, and combined LPS treatment plus FOSL1 overexpression on angiogenesis or vasculogenesis
gene expression (n = 4 per condition, by one-way ANOVA and post-hoc Tukey tests); and representative (C)
immunofluorescence images and quantification of (D) network (n = 4 per condition; by one-way ANOVA and
post-hoc Tukey tests) and (E) tubule formation of angiogenesis forming assays. *p < 0.05, **p < 0.01, ***p < 0.001
between LPS-treated and saline control; §p < 0.05, §§p < 0.01, §§§p < 0.001 between vector:LPS and FOSL1:LPS.
Data presented at mean ± standard deviation. Graphs created in SPSS 26 for Mac (https://www.ibm.com/analy
tics/spss-statistics-software) and image assembled in Adobe Illustrator 24.1.0 for Mac (https://www.adobe.com/
products/illustrator.html).
vascularization as observed in clinical BPD, by stimulating aberrant angiogenesis via TLR4-ERK-FOXC2-DLL4
signaling26,32. Others have found LPS treatment of newborn sheep to decrease lung CTGF expression and result
in abnormal lung d
 evelopment33 similar to BPD. While studies suggest inflammatory angiogenesis contributes
to vascular and alveolar remodeling in the developing lung, transcriptional regulation of sepsis-induced deviant
lung angiogenic networks implicated in pathological vascular remodeling has not been previously investigated.
In this study, we identified FOSL1 as a novel regulator of the pulmonary angiogenic response.
FOSL1 is one of several subunits that binds a Jun-family member to form the AP-1 complex. FOSL1 has
important effects in osteoclasts and disorders of bone via Wnt s ignaling34–36 and mediates anti-inflammatory
actions of some natural compounds37–39. FOSL1 is also a proto-oncogene, affecting the ability of cancer cells to
invade and metastasize in sarcomas40, squamous cells carcinomas41, melanoma42, gastric cancer43, pancreatic
cancer44, and lung c ancer44. With respect to the endothelium, it is known that Fosl1−/− embryos die and develop
vascular defects in extraembryonic tissues45. Accordingly, embryonic stem cells lacking FOSL1 differentiate into
ECs but do not form primitive capillaries or tube-like structures and FOSL1 is a required for HUVEC assembly
into vessels45. FOSL1 has also been reported as modulating angiogenesis-vasculogenesis and β3 integrin and
endothelial cell a dhesion46, but this study is the first report of FOSL1 acting as a transcriptional regulator of angiogenesis-related genes. Additionally, we extend existing work46 by including knock-down and over-expression
experiments. While an interaction between LPS and FOSL1 in modulating gefitinib-induced interstitial lung
disease has been reported47, whether LPS directly regulates FOSL1-dependent signaling and the role of FOSL1 in
mediating LPS-induced expression of key downstream angiogenic targets has not been previously investigated.
We identified PROK2, RNF213, and LRG1 as novel targets which downstream of LPS, transcriptionally regulated by FOSL1, and are implicated in angiogenesis/vasculogenesis. PROK248 is an important contributor to tumor
angiogenesis. Relevant to neonatal disease, LRG149 may contribute to the aberrant retinal vasculature observed
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in oxygen-induced retinopathy49, while RNF21350 is required for normal vascular development. Of these, LRG1
is the only overlapping reported finding in the literature where FOSL1 knockdown in HUVECs decreased LRG1
to the same degree that we found in our immortalized HPMEC line. The current study places this understanding
within the context of neonatal sepsis and implicates FOSL1 not only in embryonic development, but also potentially as a mediator of impaired vascular development in the neonatal lung. We further explored this relationship
between LPS, FOSL1, and angiogenesis/vasculogenesis with primary HPMEC and an immortalized HPMEC line
we derived from primary HPMEC. Not only did FOSL1 overexpression increase sensitivity to LPS stimulation,
FOSL1 overexpression alone induced angiogenic or vasculogenic gene expression, indicating basal regulation.
Additionally, using a ChIP assay, we demonstrated specific binding of FOSL1 to promoters of PROK2, ADAM8,
RNF213, HPX, and LRG1 downstream targets at baseline, and increased binding to PROK2, ADAM8, RNF213
promoters after LPS treatment. That all genes did not demonstrate additional binding with LPS treatment could
represent differences in time kinetics of binding after LPS treatment. Differences in the degree of LPS-induced
target gene expression between mice and HPMEC could result from the influence of other lung cell types and
cytokines in vivo, timing of i.p LPS in vivo vs. direct LPS in vitro, and encapture of several RNA transcripts by
RNA sequencing as against qRT-PCR. Similary, differences between primary HPMEC and HPMEC-Im may have
arisen because of faster proliferation in HPMEC-im and the potential for multiple gene copies in HPMEC-im.
However, the direction and amplitude of gene expression changes with LPS were not hugely different considering these variables.
A prior study in adult mice with constitutive over-expression of FOSL1 resulted in rapid death after high-dose
LPS treatment (50 mg/kg) with massive inflammation and chemokine r esponse47. However, this study did not
report any findings related to expression of angiogenesis genes or angiogenic p
 henotype47. In previous studies
from our lab, a 25-fold lower dose of i.p. LPS, as in this study, did not result in significant lethality, but a more
nuanced alteration of the angiogenic/vasculogenic phenotype with decreased lung EC population51. The dosing
we used is more consistent with the clinical scenario in preterm infants, where most infants survive Gramnegative sepsis. Herein, we propose aberrant pulmonary angiogenesis as a possible mechanism contributing to
this response. Conversely, mice deficient in Fosl1 are less susceptible to LPS-induced lung injury and mortality52,
with lower lung injury responses, fewer neutrophils, less NFκB and cJun-AP1 binding52, and lower IL-1β and
MIP-1α expression and higher IL-10 expression53. Our in vivo results in HPMEC is consistent with these study
in showing that pro-inflammatory genes induced with LPS are suppressed or increased after FOSL1 silencing or
overexpression, respectively. Our data support enhanced inflammation-induced angiogenesis/vasculogenesis
as an important mechanism of altered FOSL1 expression. Manipulation of FOSL1 expression may therefore
lead to modulation of response to inflammation. The lack of readily-available Fosl1+/− mice (Fosl1−/− mice have
embryonic lethality) and inducible EC-specific conditional Fosl1 knockout mice precluded us from performing
experiments to confirm our in vitro findings. Validation of our in vitro findings in mice with Fosl1 deficiency
in vivo would have strengthened our conclusions. Work by Schreiber et al. demonstrating a role for Fosl1 in
placental vascular d
 evelopment54 is however, consistent with our results.
This study has several strengths. Use of unbiased bioinformatics tools to generate hypotheses allowed us to
quickly identify novel targets, which could then be explored with standard laboratory techniques in both murine
and human cells, including a newly created and validated HPMEC line. Additionally, demonstration of direct
binding of FOSL1 to promoter genes, and loss- and gain-of-function approachs to examine relationships between
LPS, FOSL1 and target angiogenesis/vasculogenesis pathway genes confirmed regulation. Finally, validation
of FOSL1 as a mediator of sepsis-induced aberrant angiogenesis in human EC enhances clinical relevance. A
limitation is our initial reliance on the IPA knowledge base, which is periodically, not continuously, updated;
however, confirmation of IPA findings with more up-to-date literature searches was undertaken. Examining
how FOSL1 gets activated by LPS, investigating protein level changes of target genes, and their individual roles
in LPS-induced angiogenesis are interesting avenues for future research. Finally, while embryonic lethality of
Fosl1−/− mice precluded in vivo mechanistic validation of our results, studies in mice with conditionally-deleted
endothelial Fosl1 would strengthen our data.
In conclusion, we have identified FOSL1 as a novel, early, central target in inflammation-induced angiogenesis in primary lung EC and HPMECs, linking sepsis with expression of multiple genes involved with aberrant
angiogenesis in the developing lung, including ADAM8, LRG1, RNF213, HPX, CXCR2, PROK2, and SP100,
which may contribute to development of BPD. Taken together, these data indicate a strong, central role of FOSL1
in regulating lung EC angiogenesis in the context of inflammation. While hyperoxia and sepsis are associated
with vascular remodeling and BPD, they may alter lung angiogenesis potentially differently. Hyperoxia disrupts
angiogenesis, while sepsis may program a dysangiogenesis phenotype, wherein there might be increased but
non-directional dysmorphic a ngiogenesis22–25. Our prior work and the results of this study that systemic LPS
may program dysangiogenesis lung phenotypes that may also impair normal vascular development. The role
of FOSL1 in mediating sepsis-induced pulmonary dysangiogenesis and vascular remodeling using EC-specific
conditional FOSL1 knock down mice as well as the role of FOSL1 in regulating inflammatory angiogenesis in
other organs are topics or future research. Our data support testing whether short-term inhibition of EC-FOSLI
can serve as a therapeutic target to prevent development of vascular defects in BPD.

Methods

Cell culture and reagents. Human primary pulmonary microvascular endothelial cells (HPMEC) were
purchased from a commercial vendor (ScienCell, Carlsbad, CA) and used as previously described32. These
HPMECs were derived from lungs of newborn infants, and only cells between passages 3 and 4 were used for all
experiments. Primary HPMEC used for our experiments were derived from the lungs of 18 weeks female fetus.
HPMECs were grown in endothelial cell medium supplemented with 5% fetal bovine serum (FBS), antibiotics,
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and endothelial cell growth serum as recommended by the manufacturer in a humidified incubator containing
5% CO2 at 37 °C. Ultrapure lipopolysaccharide (LPS, 100 ng/mL) was purchased commercially from Invivogen
(San Diego, CA).

Animal model of sepsis‑induced lung injury in neonatal mice. Wild-type C57BL/6 mice were

obtained commercially from Charles River (Burlington, MA). For all animal experiments, half the litter of pups
were injected with LPS (2 mg/kg) and other half injected with sterile saline (controls) intra-peritoneally (i.p.)
(Sigma, St Louis, MO) served as littermate controls, as previously p
 erformed51. We did not observe any mortality
in our experiments. The pups were left with the dam and closely monitored for signs of distress for half a hour,
and then they were observed briefly once more on the same day for the 24 h experiments. All animal experiments were performed on mouse pups on DOL 4. Mice were sacrificed using a i.p. injection of pentobarbital
(100 mg/kg) and were exsanguinated after cessation of heartbeat. The lungs were harvested for EC isolation.

Isolation of murine endothelial cells.

Each endothelial preparaton was from pooled lungs of two
C57BL/6 pups (4 days old). 3–4 biological replicates, 6–8 mice/condition was used for experiments. The protocol for the isolation of mouse lung EC was described p
 reviously55. Briefly, the lungs from euthanized pups were
minced with scissors in DMEM and transferred to pre-warmed 1 mg/mL collagenase solution and rotated at
37 °C for 45 min55. The digested mixture was passed through a 14 g cannula several times, strained through a
70 µm cell strainer, and washed with a 20% FBS solution55. The supernatant was then centrifuged at 400 × g for
5 min and the pellet was resuspended with 0.1% bovine serum albumin55. The endothelial cells were isolated
with anti-PECAM-1 antibody-conjugated Dynabeads (Thermo-Fisher, Rockford, IL) on a rocker for 15 min
at room temperature as per the manufacturer’s protocol. RNA was extracted following standard protocol as
described below.

Generation of HPMEC cell line. Primary HPMEC (male, 19 week fetus) were immortalized using SV40
large T antigen. Lentiviral transduction (Applied Biological Materials (ABM), Richmond, BC, Canada). These
endothelial cells were cultured in endothelial cell media as above and only cells less than passage ten were used.
To validate immortalized HPMEC (HPMEC-im), we cultured cells on coverslips and stained them with antibodies of endothelial markers, such as CDH5, ERG and VWF. The slides were used for IF staining using the primary antibodies (Abcam, Cambridge, MA) with the corresponding Alexa Fluor secondary antibodies (ThermoFisher). The slides mounted in Prolong Gold with DAPI (Thermo-Fisher), which stains the nucleus. We also
verified IM HMPEC with Alexa Fluor 488 AcLDL uptake experiment. Images were taken at 63× magnification
using a Zeiss LSM510 confocal microscope with an attached camera.
RNA isolation and cDNA generation. Total RNA was extracted from HPMECs and mouse lung EC or
tissue using the PureLink RNA Mini Kit (Thermo-Fisher) following the manufacturer’s instructions as previously described32. cDNA was synthesized from 1 μg of RNA using a SuperScript IV First-Strand Synthesis Kit
(Thermo-Fisher) per the manufacturer’s recommendations.
RNA‑Seq.

Total RNA was extracted from mouse lung EC using the mirVana miRNA isolation kit (ThermoFisher). RNA sequencing was performed on a HiSeq 1,500 system (Illumina, San Diego, CA). Mapping of RNASeq reads and transcript assembly and abundance estimation were conducted using the Tuxedo Suite software
package (Broad Institute, Cambridge, MA) as previously described56–58. DAVID was used for biological function analysis. Heatmaps were generated from heatmapper.ca/expression and are scaled by row and hierarchically clustered by average linkage distance via Euclidean measurement. Full sequencing data (BioProject ID
PRJNA600007) are available online at https://www.ncbi.nlm.nih.gov/bioproject/600007.

Ingenuity pathway analysis. Networks were generated through the use of IPA (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis)59.

RT‑PCR. Primary mouse pulmonary microvascular EC were used to validate RNA-Seq data. Immortalized

and primary human pulmonary microvascular EC were used for mechanistic studies. RT-PCR was performed
on cDNA using PowerUp SYBR Green master mix (Thermo-Fisher) and appropriate primers with the SYBR
green method on a Thermo Fisher QuantStudio 3. Mouse primers for Fosl1, Adam8, Cxcr2, Plac8, Fcgr3, Hpx,
Rnf213, and Prok2, and human primers for CXCL10, CXCR2, ADAM8, FOSL1, FCGR3, FCGR2, EFHD2, LRG1,
HIF3A, MDK, IL1A, SP100, PROK2, HPX, IL8, ICAM1, and TNF were pre-validated and purchased commercially from Sigma. Actin or 18S were used as housekeeping genes. Relative gene expression was calculated using
the Pflaffl method60.

JASPAR analysis. The promotor sequences (about 2 kB region upstream of transcription start site) were

downloaded from NCBI genome browser. FOSL1 binding sites on the promoters were predicted by JASPAR
201861 with a threshold of 0.9.

FOSL1 plasmid generation and transfection. Human FOSL1 cDNA was amplified and cloned into

pIRES-EGFP-Puro (Addgene, Cambridge, MA) with 5′-ACTGCTAGCCACCATGACCTCAACCGGCCA
GGATTCCA-3′ and 5′-TGAGAGCTCTTAGTGTGGGTGGGGCATATCCTCCCCAAA-3′ as performed
previously51. HPMEC grown in 6-well tissue culture plates were transfected overnight with 2 µg of the indicated
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plasmids or empty plasmids (mock) with Lipofectamine 3,000 (Thermo-Fisher) as per the manufacturer’s protocol. Cells were allowed to recover for 24 h, and were then treated with LPS for 6 or 24 h. Cell lysates were used
for RNA quantification by RT-PCR.

Chromatin immunoprecipitation assay.

The ChIP assay was performed as previously d
 escribed26.
Briefly, the HPMEC cells were fixed with 1% formaldehyde for 10 min after 7 h LPS treatment at 500 ng/mL. The
Pierce Magnetic ChIP Kit wa used according to the manufacturer’s instructions. The FOSL1 antibody (PCRPFOSL1-1E3) was obtained from Hybridoma Bank. The ChIP products were analyzed by quantitative real-time
PCR. The sequences of primers used in RT-PCR are shown below: ADAM8, sense-TCCCAGGATAACGTC
CGAG and antisense-GAGTCAGGGAACTGCACG; HPX, sense-CATCTGTGAGGGATCAGGG and antisense-TGTGAGATTTGCCTAGTGAGTC; LRG1, sense-AGGTGTTCATGACAGAGCTG and antisense-CCA
ATAGTGAGTAATGCCAAACG; PROK2, sense-AGCAAGTTCGGTGTGGTC and antisense-AAGTGACAG
ATTTGCCCTCC; RNF213, sense-TGCCCAACTAGCGTTCTAAAG and antisense-GTCTCAAACTCCTGA
CCTCAG.

siRNA‑mediated FOSL1 gene silencing. siRNA sequences targeting human FOSL1 (siFOSL1) and

control siRNA were purchased from Santa Cruz Biotechnology (SCBT) (Dallas, TX) and gene silencing was
performed following manufacturers recommendations as reported b
 efore32,62. For the non-silenced cells, control
54,55
siRNA (SCBT) was used according to the manufacturer’s protocol . Briefly, HPMECs were cultured until 80%
confluent and the cells were incubated with 8 μg of either control siRNA or siFOSL1 in transfection medium for
16 h and was changed to normal ECM54,55. The cells were grown for another 48 h and treated with LPS for the
experiments. The efficiency of the silencing was determined by qPCR.

Angiogenic tube and network formation assay on Matrigel.

The lung EC in vitro angiogenesis network formation assay using a 2 dimensional matrigel platfrom was performed as described p
 reviously32,63. Briefly,
HPMEC were grown to ~ 80% confluence, and then subsequently silenced with siFOSL1 or control siRNA32,63.
Cells were treated with LPS for 10 h. Subsequently, cells were detached with TrypLE Express (Thermo-Fisher),
re-suspended in basal ECM, and 6 × 104 cells were plated onto a 24-well Matrigel-coated plate (Corning, Corning, MA)32,63. After 12 h, angiogenesis was assessed with the use of calcein AM fluorescent dye (Corning), per
the manufactuer’s protocol, to enhance the visibility of tube and network formation. Angiogenic quantification
was evaluated by counting the number of tube and network formations in one quadrant (the same one for each
condition) and multiplying by four32,63. For measurements, tubes were considered to be tubular structures connecting two cell clusters, and networks were counted by cell clusters with at least three tubular structures emanating out. Representative images were taken using an Olympus 1 × 71 fluorescence microscope with attached
camera at 4× zoom.

Statistical analysis. All experiments were performed with ≥ 3 biological replicates, as indicated in figure

legends, and ≥ 2 technical replicates for RT-PCR. Data were analyzed with SPSS version 26 for Mac (IBM). The
Shapiro–Wilk test was used to determine normality. Comparisons between two groups were made by one-sample, two-tailed Student’s t test or one-sample Wilcoxon signed rank test for parametric or non-parametric data,
respectively. Comparisons between three or more groups, as for the FOSL1 overexpression and silencing studies,
were analyzed by one-way ANOVA and post-hoc Tukey tests for multiple comparisons. All values are expressed
as mean ± 1 standard deviation. P values < 0.05 were considered statistically significant.

Ethical approval. Care of mice before and during experimental procedures was conducted in accordance
with the policies at the University of Missouri-Kansas City Lab Animal Resource Center and the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Protocols had prior approval from the
University of Missouri-Kansas City Institutional Animal Care and Use Committee.

Data availability

The datasets generated during and analysed during the current study are available in the BioProject repository,
https://www.ncbi.nlm.nih.gov/bioproject/600007.
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